MRD-Driven Adaptive Strategy With Upfront Daratumumab-based Therapy in Newly Diagnosed Multiple Myeloma

Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Proportion of Participants Who Achieve MRD Negativity Either After Induction or, if Still MRD-positive After Induction, After Consolidation at 36 weeks. Started Oct 2020; status: active, not recruiting.